CagriSema vs Exenatide
A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CagriSema
CagriSema is Novo Nordisk's investigational fixed combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist). By pairing two complementary appetite pathways, it produced roughly 20–23% weight loss in trials. It was filed with the FDA in December 2025 but is not yet approved — and notably missed non-inferiority against tirzepatide in a head-to-head study.
Full profileExenatide
First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits.
Full profile| CagriSema | Exenatide | |
|---|---|---|
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Also known as | Cagrilintide + Semaglutide, AM833 + semaglutide, amylin/GLP-1 combination | Byetta, Bydureon, AC2993, exendin-4 |
| Evidence | Investigational (in trials) | FDA-approved |
| Dosing range | 0.25mg–2.4mg mg, once weekly subcutaneous (each component 2.4mg at target) | 5mcg–2mg (weekly ER) mcg, Twice daily (immediate-release) or once weekly (extended-release) |
| Administration | Subcutaneous injection (weekly) | Subcutaneous injection |
| Key side effects | Nausea (most common, dose-dependent), Vomiting, Diarrhea or constipation, Decreased appetite | Nausea (most common, especially initial weeks), Vomiting, Diarrhea, Injection site nodules (extended-release formulation) |
| Cited sources | 2 references | 2 references |
Key differences
- Evidence level differs: CagriSema is investigational (in trials), while Exenatide is fda-approved.
- Administration: CagriSema — Subcutaneous injection (weekly); Exenatide — Subcutaneous injection.
- Dosing units differ: CagriSema is dosed in mg, Exenatide in mcg — they operate at different scales.
- Frequency: CagriSema is typically once weekly subcutaneous (each component 2.4mg at target); Exenatide is Twice daily (immediate-release) or once weekly (extended-release).
How each works
CagriSema
CagriSema combines amylin-receptor agonism (cagrilintide — satiety and gastric emptying via the area postrema/hypothalamus) with GLP-1 agonism (semaglutide), two non-overlapping appetite mechanisms. The REDEFINE 1 and 2 trials supported a December 2025 FDA filing for weight management. However, the open-label REDEFINE-4 head-to-head trial showed 23.0% weight loss vs 25.5% for tirzepatide 15 mg, missing its primary non-inferiority endpoint. An FDA decision is expected in late 2026.
Exenatide
Exenatide was identified from Gila monster (Heloderma suspectum) venom as exendin-4, a peptide with ~53% homology to human GLP-1 but with DPP-4 resistance enabling longer activity. Clinical trials demonstrated HbA1c reductions of 0.8–1.0%, weight loss of 2–4kg, and cardiovascular safety (EXSCEL trial showed non-inferiority). The extended-release microsphere formulation achieved comparable efficacy with once-weekly dosing.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.